Videos / Fluticasone furoate, umeclidinium and vilanterol dry powder triple therapy inhaler
In this Product Explainer, Respiratory Physician Dr Kwok Yan explains the role of fluticasone furoate, umeclidinium and vilanterol dry powder triple therapy inhaler for the maintenance treatment of asthma in adult patients who are not adequately controlled with an ICS+LABA (7 mins).
This educational activity was developed by Healthed at the request of and with funding from GSK.
PM-AU-FVU-OGM-220003 approved June 2022

Abnormal LFTs – Practical Cases Expert Q&A

MRAs for Heart Failure Update - New Developments

COPD Exacerbation – Inhaled steroids vs Pneumonia Risks – It's Not Black and White

Practical Strategies to Increase Vaccination Rates This Flu Season